“Talk to me before you believe anything!”, Thomas Cromwell (played by Mark Rylance) tells his monarch and master Henry VIII (played by Damien Lewis) in a pivotal scene in the penultimate episode of the BBC adaptation of The Mirror and the Light, the 900-page third act in Hilary Mantel’s acclaimed Tudor drama. It is the last of their candid exchanges before the criticism from his enemies becomes deafening and Cromwell is seized, stripped of his offices of state and taken into custody. For nearly a decade, Cromwell, has strived to speak the truth to his all-mighty monarch. It has set him apart from all those packed into the palace antechambers and pitching for a seat on the king’s council: aristocrats who were there by hereditary right, churchmen because of their office and favourites whose rise invariably was as fast as their fall. Shrewd realpolitik was why Cromwell’s assent to the top seemed unstoppable and the reason Henry grew to like him. “By St Loy, this man has stomach, this man has gall!,” the now-ailing king recalls, in Peter Straughan’s script, of his first impression. Establishing the facts of the matter, however uncomfortable for whichever party, remained this self-taught lawyer’s stock-in-trade. But by 1540 Henry lacked the bodily strength and mental self-assurance to accept them anymore. “I have changed, Thomas. You, not so much.” Looking for something good? Cut through the noise with a carefully curated selection of the latest releases, live events and exhibitions, straight to your inbox every fortnight, on Fridays. Sign up here . “To retrieve history,” Mantel argued in her 2017 Reith lecture , “we need rigour, unsparing devotion and an impulse to scepticism.” Stomach and gall. Enough, Mantel urged, to unsettle the stereotypes, even to “de-centre” the “grand narrative”. The determination Mantel found in Cromwell’s letters, to “decipher the bottom of their heart ... if by any wisdom it may be drawn out” to politician Sir Thomas Wyatt in 1537 suggested that he could be a fresh guide to this period of Tudor history, long distorted by caricature and cliché. As sharp as the dagger secreted in his doublet and an outsider on the inside, through Cromwell’s eyes it might be refocused. Mantel believed the novelist could best evoke an alternative point-of-view. “The records do ... throw up some facts but they are not the whole truth.” Lived experience, she argued, lies in the “gaps, the erasures and silences” of the documented past, speeches unrecorded, thoughts unspoken. Fiction breathes them back into life, lifting the veil from the “vital”, “interior” view of lives long past. Mantel’s conviction was so strong that she was inclined to criticise readers for clinging to “the first history they learn” and for their “unreasonable” refusal to commit to the novelist’s telling of it until they can be sure of its reliability. “I report the outer world faithfully,” she explained “but my chief concern is the interior drama of my characters’ lives.” In their adaptation Straughan and director Peter Kosminsky have followed Mantel’s manifesto to the letter. They present the “outer world” with precision. Unlike any of his predecessors, Kosminky has taken immense pains to locate the action in landscapes and environments which the historical figures would have recognised. His choices are clever, including Gloucester Cathedral, surely the most complete and unaltered Benedictine cloister in Britain, standing in for the lost abbey of Shaftesbury and Horton Court in Gloucestershire for Cromwell’s city of London chambers at the Austin Friary, which, in spite of its religious status, is known to have looked like a cluster of town houses. Casting director Robert Sterne has peopled the scene with performers uncannily close in age and aspect to the figures they play. Thomas Brodie Sangster (Rafe Sadler) and Harry Melling (Thomas Wriothesley), both in their 30s, capture their subjects perfectly. Damien Lewis still seems to walk in Henry’s now halting footsteps, although the hiatus since the 2015 series means he is three years the king’s senior. Only Timothy Spall (Thomas Howard) is jarring. He is 67, as Howard was in 1540, but squat, jowly and with a one-note anger, which makes him less like a noble duke and more like Alice through the Looking Glass’s Queen. But in spite, or perhaps because, of the studied skill of this practised team, this visualisation does expose the tensions – in fact, downright contradictions – in Mantel’s treatment of the past. In her Reith Lectures she declared: “Don’t lie, don’t go against known facts. Historical truth cuts against the storyteller’s instinct. Your characters are never how or where you’d like them to be.” Yet Straughan’s adept précis of the 900-page book shows how often she shrugged off her own counsel. The visible, vocal presence of Cardinal Thomas Wolsey (Jonathan Pryce), dead a full six years before the events of episode one unfolded, is conspicuously clumsy, muddling any viewer confronting the subject for the first time. Of course, it is a device, but if the “outer world” seems unstable how can they make sense of the “interior drama”? In Cromwell’s marriage proposal to the cardinal’s cast-off daughter, Dorothy Clancy (episode two) Mantel places her characters where she would like them to be and to say what she would like them to say. Her “going against known facts” is less troubling than her narrow line-of-sight, which the clipped script and slick camerawork set in sharp relief. The historical dramas of Cromwell’s last years in power were armed rebellion (the Pilgrimage of Grace) and the greatest displacement of people and livelihoods since the Norman Conquest (the dissolution of the monasteries), a stop-start process which de-stabilised the Tudor regime as much as its subjects. In Mantel’s story, they are little more than noises out of frame. The climate in court and country became so febrile in the face of these episodes because positions on them in every part of society were uncertain even, perhaps especially, in the mind of the king himself. Thomas Cromwell knew this better than any other contemporary witness. Mantel, whatever she claimed to the contrary, maintained the “grand narrative” of Catholic versus Protestant, traditional aristocrat versus modernising commoner. Like King Henry, she did not keep listening to her subject for long enough. James Clark receives funding for historical research from the Arts & Humanities Research Council and consults on and collaborates in research and visitor engagement for the National Trust. He is a Fellow of the Royal Historical Society and of the Society of Antiquaries of London.gstar288 。

Boston College holds on down stretch to top Fairleigh DickinsonPhase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE Amgen

NoneWith their new movie Y2K, Kyle Mooney and Evan Winter invite you to 1999’s deadliest partyInformation Commissioner Gitanjali Gutierrez issued four decisions regarding the Bermuda Civil Aviation Authority, Information & Digital Technologies Department, Ministry of Health Headquarters, and the Cabinet Office Headquarters. A spokesperson said, “On 29 November 2024, Information Commissioner Gitanjali Gutierrez issued Decision 32/2024, Bermuda Civil Aviation Authority, Decision 33/2024, Information & Digital Technologies Department, Decision 34/2024, Ministry of Health Headquarters, and Decision 35/2024, The Cabinet Office Headquarters. “In Decision 32/2024, the Information Commissioner considered the Bermuda Civil Aviation Authority’s decision on a PATI request seeking airport audit and inspection reports and other documentation by the Authority’s technical officers. Commissioner Gutierrez affirmed the Authority’s decision to administratively deny the PATI request, in full, because she agreed that processing the request would have created a substantial and unreasonable interference with or disruption to the Authority’s other work. The parties had been unable to agree on a reasonably narrowed request scope, which would have allowed the Authority to continue processing the request. Decision 32/2024 did not require the Authority to take further action. “In Decisions 33/2024 and 34/2024, the Information Commissioner assessed two public authorities’ decisions on separate PATI requests seeking records on the same topic. The Applicants asked for all records about tech companies BPMS, InnoFund, and i3 and Fastpass, a port-of-entry system project. Originally, each public authority had decided their records were exempt from public access due to a legal claim the tech companies had filed in court against the Government. “During these reviews, as most of the records contained the companies’ third-party information, the Information Commissioner’s Office also notified the third parties and considered their submissions. Ultimately, Commissioner Gutierrez was not persuaded by either public authority’s reliance on the exemption about prejudice to a trial or adjudication. But Decision 33/2024 found that the Information & Digital Technologies Department was justified, in part, in relying on an exemption to protect public authorities’ deliberative information from public disclosure. Similarly, Decision 34/2024 found that the Ministry of Health Headquarters was justified, in part, in relying on an exemption to prevent public disclosure of information that could have prejudiced negotiations. After applying the personal information exemption to the sets of remaining records in both reviews, Commissioner Gutierrez concluded that each public authority’s decision was upheld in part. The Information & Digital Technologies Department and the Ministry of Health Headquarters each have been ordered to disclose certain records by 15 January 2025. “In Decision 35/2024, the Information Commissioner found that the Cabinet Office Headquarters had failed to issue an internal review decision on a PATI request seeking records about government spending on a specific PATI request and PATI consultants. The Cabinet Office Headquarters has been ordered to issue the Applicant its internal review decision by 3 January 2025.” : ,

When Katja Vogt considers a Jaguar, she pictures a British-made car purring confidently along the Italian coastline — a vision of familiarity that conveys "that dreaming, longing feeling we all love." She's not sure what to think about Jaguar now after the 89-year-old company announced a radical rebranding that featured loud colors and androgynous people — but no cars. Jaguar, the company says, will now be JaGUar. It will produce only electric vehicles beginning in 2026. Bad attention is good attention, Jaguar execs would appear to believe. The car brand has prompted mockery online for posting a glitzy ad without a single car in it. Say goodbye to British racing green, Cotswold Blue and black. Its colors are henceforth electric pink, red and yellow, according to a video that sparked backlash online. Its mission statement: "Create exuberance. Live vivid. Delete ordinary. Break moulds." "Intrigued?" @Jaguar posted on social media. People are also reading... "Weird and unsettled" is more like it, Vogt wrote on Instagram. "Especially now, with the world feeling so dystopian," the Cyprus-based brand designer wrote, "a heritage brand like Jaguar should be conveying feelings of safety, stability, and maybe a hint of rebellion — the kind that shakes things up in a good way, not in a way that unsettles." After 155 years, the Campbell Soup company is changing its name Jaguar was one of several iconic companies that announced significant rebrandings in recent weeks, upending a series of commercial — and cultural — landmarks by which many modern human beings sort one another, carve out identities and recognize the world around them. Campbell's, the 155-year-old American icon that artist Andy Warhol immortalized in pop culture decades ago, is ready for a new, soupless name. Comcast's corporate reorganization means there will soon be two television networks with "NBC" in their name — CNBC and MSNBC — that will no longer have any corporate connection to NBC News, a U.S. legacy news outlet. CNBC One could even argue the United States itself is rebranding with the election of former President Donald Trump and Republican majorities in the House and Senate. Unlike Trump's first election in 2016, he won the popular vote in what many called a national referendum on American identity. Are we, then, the sum total of our consumer decisions — what we buy, where we travel and whom we elect? Certainly, it's a question for those privileged enough to be able to afford such choices. Volumes of research in the art and science of branding — from "brandr," an old Norse word for burning symbols into the hides of livestock — say those factors do contribute to the modern sense of identity. So rebranding, especially of heritage names, can be a deeply felt affront to consumers. "It can feel like the brand is turning its back on everything that it stood for — and therefore it feels like it's turning its back on us, the people who subscribe to that idea or ideology," said Ali Marmaduke, strategy director with the Amsterdam-based Brand Potential. He said cultural tension — polarization — is surging over politics, wars in Russia and the Mideast, the environment, public health and more, creating what Marmaduke said is known as a "polycrisis": the idea that there are several massive crises converging that feel scary and complex. Campbell's soups "People are understandably freaked out by that," he said. "So we are looking for something that will help us navigate this changing, threatening world that we face." Trump's "Make America Great Again" qualifies. So did President Joe Biden's "Build Back Better" slogan. Campbell's soup itself — "Mmm Mmm Good" — isn't going anywhere, CEO Mark Clouse said. The company's new name, Campbell's Co., will reflect "the full breadth of our portfolio," which includes brands like Prego pasta sauce and Goldfish crackers. None of the recent activity around heritage brands sparked a backlash as ferocious as Jaguar's. The company stood as a pillar of tradition-loving British identity since World War II. The famous "leaper" cat Jaguar logo is pictured in 2019 at the Auto show in Paris, France. Jaguar said its approach to the rebrand was rooted in the philosophy of its founder, Sir William Lyons, to "copy nothing." What it's calling "the new Jaguar" will overhaul everything from the font of its name to the positioning of it's famous "leaper" cat. "Exuberant modernism" will "define all aspects of the new Jaguar world," according to the news release. The approach is thought to be aimed at selling fewer cars at a six-figure price point to a more diverse customer base. The reaction ranged from bewilderment to hostility. Memes sprouted up likening the video to the Teletubbies, a Benetton ad and — perhaps predictably — a bow to "woke" culture as the blowback intersected with politics. Here’s what the Pizza Hut of the future looks like Tropicana fans are ditching the brand after a orange juice bottle redesign Get the latest local business news delivered FREE to your inbox weekly.

Georgia has a chance to post its best start to a season in 94 years ahead of its home meeting with South Carolina State in Athens, Ga., on Sunday. Georgia (11-1) hasn't appeared in the NCAA Tournament in 10 seasons and hasn't won a tournament game since 2002, but the Bulldogs seem primed to make a return. The Bulldogs have won six straight games and a seventh would mark their best start since beginning 13-0 in the 1930-31 campaign. Georgia hasn't played since a Dec. 22 home win over Charleston Southern. Head coach Mike White knows the intensity of the schedule will soon increase as Southeastern Conference play revs up, but that's not to say his team will overlook its next opponent. "We've had a much-needed break, both mentally and physically," White said. "Our guys need to get away from it a little bit, miss it, then come back rejuvenated for one more tune up for the grind of the SEC -- the best league in the country. But we'll be prepared for South Carolina State. They're dangerous, they play really hard, they've been really competitive. They're another good team." Adding to Georgia's success has been the play of De'Shayne Montgomery. After being academically ineligible for the first 10 games of the season, the Mount St. Mary's transfer has averaged 19 points per game in two contests. Asa Newell follows with 15.8 points in 12 games, while fellow Mount St. Mary's transfer Dakota Leffew chips in 12.9. South Carolina State (6-8) will play its fourth road game of a six-game stretch away from home. The other Bulldogs prepare for their final regular season meeting with a power conference team following losses at South Carolina Upstate and Xavier. South Carolina State faces Morgan State on Jan. 4 to start Mid-Eastern Athletic Conference play. Led by third-year head coach Erik Martin, the team boasts a rare roster figure in today's college basketball landscape. "We brought back 90 percent of our returnable student athletes this year," Martin said. "I can pretty much guarantee I'm the only person in America that did that." Sophomore Drayton Jones leads the team with 13 points per game, followed by Omar Croskey's 9.4. Georgia is 2-0 all-time against South Carolina State, last earning a 76-60 win in Nov. 2021. --Field Level MediaAs the high-bandwidth memory (HBM) market continues to grow, projected to reach $33 billion by 2027, the competition between and SK Hynix intensifies. Tesla is fanning the flames as it has reportedly reached out to both Samsung and SK Hynix, two of South Korea's largest memory chipmakers, seeking samples of its next-generation HBM4 chips. Now, a report from the claims Tesla plans to evaluate these samples for potential integration into its custom-built Dojo supercomputer, a critical system designed to power the company’s ambitions, including its self-driving vehicle technology. Tesla’s ambitious AI and HBM4 plans The Dojo supercomputer, driven by Tesla’s proprietary D1 AI chip, helps train the neural networks required for its Full Self-Driving (FSD) feature. This latest request suggests that Tesla is gearing up to replace older HBM2e chips with the more advanced HBM4, which offers significant improvements in speed, power efficiency, and overall performance. The company is also expected to incorporate HBM4 chips into its AI data centers and future self-driving cars. Samsung and SK Hynix, long-time rivals in the memory chip market, are both preparing prototypes of HBM4 chips for Tesla. These companies are also aggressively developing customized HBM4 solutions for major U.S. tech companies like , Meta, and . According to industry sources, SK Hynix remains the current leader in the high-bandwidth memory (HBM) market, supplying HBM3e chips to and holding a significant market share. However, Samsung is quickly closing the gap, forming partnerships with companies like Taiwan Semiconductor Manufacturing Company (TSMC) to produce key components for its HBM4 chips. SK Hynix seems to have made progress with its HBM4 chip. The company claims that its solution delivers 1.4 times the bandwidth of HBM3e while consuming 30% less power. With a bandwidth expected to exceed 1.65 terabytes per second (TB/s) and reduced power consumption, the HBM4 chips offer the performance and efficiency needed to train massive AI models using Tesla’s Dojo supercomputer. The new HBM4 chips are also expected to feature a logic die at the base of the chip stack, which functions as the control unit for memory dies. This logic die design allows for faster data processing and better energy efficiency, making HBM4 an ideal fit for Tesla’s AI-driven applications. Both companies are expected to accelerate their HBM4 development timelines, with SK Hynix aiming to deliver the chips to customers in late 2025. Samsung, on the other hand, is pushing its production plans with its advanced 4-nanometer (nm) foundry process, which could help it secure a competitive edge in the global HBM market. Via

Israeli police set to probe Netanyahu’s wife over ‘harassment of witnesses’

The 26-year-old man charged in last week’s killing of UnitedHealthcare’s CEO appeared in a Pennsylvania courtroom on Tuesday, where he was denied bail and his lawyer said he'd fight extradition to New York City, where the attack happened. Luigi Nicholas Mangione was arrested Monday in last Wednesday's attack on Brian Thompson after they say a worker at a McDonald’s in Altoona, Pennsylvania, alerted authorities to a customer who resembled the suspected gunman. When arrested, Mangione had on him a gun that investigators believe was used in the attack and writings expressing anger at corporate America, police said. People are also reading... As Mangione arrived at the courthouse Tuesday, he struggled with officers and shouted something that was partly unintelligible but referred to an “insult to the intelligence of the American people.” Mangione is being held on Pennsylvania charges of possession of an unlicensed firearm, forgery and providing false identification to police. Manhattan prosecutors have charged him with five counts, including murder, criminal possession of a weapon and criminal possession of a forged instrument. Here are some of the latest developments: What's the latest? Wearing an orange jumpsuit, Mangione mostly stared straight ahead during the hearing, occasionally consulting papers, rocking in his chair, or looking back at the gallery. At one point, he began to speak to respond to the court discussion but was quieted by his lawyer. Judge David Consiglio denied bail to Mangione, whose attorney, Thomas Dickey, told the court that his client did not agree to extradition and wants a hearing on the matter. Blair County (Pennsylvania) District Attorney Peter Weeks said that although Mangione's fighting extradition will create “extra hoops” for law enforcement to jump through, it won’t be a substantial barrier to sending him to New York. What evidence has been gathered? In addition to a three-page, handwritten document that suggests he harbored “ill will toward corporate America,” NYPD Chief of Detectives Joseph Kenny said Monday that Mangione also had a ghost gun, a type of weapon that can be assembled at home and is difficult to trace. Officers questioned Mangione, who was acting suspiciously and carrying multiple fraudulent IDs, as well as a U.S. passport, New York Police Commissioner Jessica Tisch said. Officers also found a sound suppressor, or silencer, “consistent with the weapon used in the murder,” she said. He had clothing and a mask similar to those worn by the shooter and a fraudulent New Jersey ID matching one the suspect used to check into a New York City hostel before the shooting, the commissioner said. What do we know about Mangione? Kenny said Mangione was born and raised in Maryland, has ties to San Francisco and that his last known address is in Honolulu. Mangione, who was valedictorian of his Maryland prep school, earned undergraduate and graduate degrees in computer science in 2020 from the University of Pennsylvania, a university spokesman told The Associated Press on Monday. Mangione comes from a prominent Maryland family. His grandfather Nick Mangione, who died in 2008, was a successful real estate developer. One of his best-known projects was Turf Valley Resort, a sprawling luxury retreat and conference center outside Baltimore that he purchased in 1978. Mangione likely was motivated by his anger with what he called “parasitic” health insurance companies and a disdain with corporate greed, said a law enforcement bulletin obtained by The Associated Press. He wrote that the U.S. has the most expensive healthcare system in the world and that the profits of major corporations continue to rise while “our life expectancy” does not, according to the bulletin, which was based on a review of the suspect’s hand-written notes and social media postings. The defendant appeared to view the targeted killing of the UnitedHealthcare CEO as a symbolic takedown and may have been inspired by “Unabomber” Ted Kaczynski, whom he called a “political revolutionary,” the document said. The shooting and a quick escape Police said the person who killed Thompson left a hostel on Manhattan's Upper West Side at 5:41 a.m. on Wednesday. Eleven minutes later, he was seen on surveillance video walking back and forth in front of the New York Hilton Midtown, wearing a distinctive backpack. At 6:44 a.m., he shot Thompson at a side entrance to the hotel, fled on foot, then climbed aboard a bicycle and within four minutes had entered Central Park, according to police. Another security camera recorded the gunman leaving the park near the American Museum of Natural History at 6:56 a.m. still on the bicycle but without the backpack, police said. After getting in a taxi, he headed north to a bus terminal near the George Washington Bridge, arriving at around 7:30 a.m. From there, the trail of video evidence runs cold. Police have not located video of the suspect exiting the building, leading them to believe he likely took a bus out of town. Police said they are still investigating the path the suspect took to Pennsylvania. “This just happened this morning," Kenny said. "We’ll be working, backtracking his steps from New York to Altoona, Pennsylvania,” Kenny said. Associated Press reporters Lea Skene, Matt O'Brien, Sean Murphy and Cedar Attanasio contributed to this report. The business news you needSouth Africa Music Market Report 2024 - Digital and Physical Music Sales, Major Streaming Services, Streaming Income Challenges and Industry Developments

When Katja Vogt considers a Jaguar, she pictures a British-made car purring confidently along the Italian coastline — a vision of familiarity that conveys "that dreaming, longing feeling we all love." She's not sure what to think about Jaguar now after the 89-year-old company announced a radical rebranding that featured loud colors and androgynous people — but no cars. Jaguar, the company says, will now be JaGUar. It will produce only electric vehicles beginning in 2026. Bad attention is good attention, Jaguar execs would appear to believe. The car brand has prompted mockery online for posting a glitzy ad without a single car in it. Say goodbye to British racing green, Cotswold Blue and black. Its colors are henceforth electric pink, red and yellow, according to a video that sparked backlash online. Its mission statement: "Create exuberance. Live vivid. Delete ordinary. Break moulds." "Intrigued?" @Jaguar posted on social media. "Weird and unsettled" is more like it, Vogt wrote on Instagram. "Especially now, with the world feeling so dystopian," the Cyprus-based brand designer wrote, "a heritage brand like Jaguar should be conveying feelings of safety, stability, and maybe a hint of rebellion — the kind that shakes things up in a good way, not in a way that unsettles." Jaguar was one of several iconic companies that announced significant rebrandings in recent weeks, upending a series of commercial — and cultural — landmarks by which many modern human beings sort one another, carve out identities and recognize the world around them. Campbell's, the 155-year-old American icon that artist Andy Warhol immortalized in pop culture decades ago, is ready for a new, soupless name. Comcast's corporate reorganization means there will soon be two television networks with "NBC" in their name — CNBC and MSNBC — that will no longer have any corporate connection to NBC News, a U.S. legacy news outlet. CNBC One could even argue the United States itself is rebranding with the election of former President Donald Trump and Republican majorities in the House and Senate. Unlike Trump's first election in 2016, he won the popular vote in what many called a national referendum on American identity. Are we, then, the sum total of our consumer decisions — what we buy, where we travel and whom we elect? Certainly, it's a question for those privileged enough to be able to afford such choices. Volumes of research in the art and science of branding — from "brandr," an old Norse word for burning symbols into the hides of livestock — say those factors do contribute to the modern sense of identity. So rebranding, especially of heritage names, can be a deeply felt affront to consumers. "It can feel like the brand is turning its back on everything that it stood for — and therefore it feels like it's turning its back on us, the people who subscribe to that idea or ideology," said Ali Marmaduke, strategy director with the Amsterdam-based Brand Potential. He said cultural tension — polarization — is surging over politics, wars in Russia and the Mideast, the environment, public health and more, creating what Marmaduke said is known as a "polycrisis": the idea that there are several massive crises converging that feel scary and complex. Campbell's soups "People are understandably freaked out by that," he said. "So we are looking for something that will help us navigate this changing, threatening world that we face." Trump's "Make America Great Again" qualifies. So did President Joe Biden's "Build Back Better" slogan. Campbell's soup itself — "Mmm Mmm Good" — isn't going anywhere, CEO Mark Clouse said. The company's new name, Campbell's Co., will reflect "the full breadth of our portfolio," which includes brands like Prego pasta sauce and Goldfish crackers. None of the recent activity around heritage brands sparked a backlash as ferocious as Jaguar's. The company stood as a pillar of tradition-loving British identity since World War II. The famous "leaper" cat Jaguar logo is pictured in 2019 at the Auto show in Paris, France. Jaguar said its approach to the rebrand was rooted in the philosophy of its founder, Sir William Lyons, to "copy nothing." What it's calling "the new Jaguar" will overhaul everything from the font of its name to the positioning of it's famous "leaper" cat. "Exuberant modernism" will "define all aspects of the new Jaguar world," according to the news release. The approach is thought to be aimed at selling fewer cars at a six-figure price point to a more diverse customer base. The reaction ranged from bewilderment to hostility. Memes sprouted up likening the video to the Teletubbies, a Benetton ad and — perhaps predictably — a bow to "woke" culture as the blowback intersected with politics. Get local news delivered to your inbox!

Pune: The civic body plans to step up action against littering in public places by doubling the number of flying squad vehicles. Ten new vehicles will be added to the flying squads, which will catch offenders found violating solid waste management guidelines for public sanitation. Earlier, PMC had only 8 vehicles. Fines will be levied for offences like spitting in public places, using banned plastic, garbage burning, and throwing trash in public areas. Pune Municipal Corporation (PMC) has filed over 72,000 cases and collected fines of Rs 4 crore from violators since Oct 2023. PMC has confiscated nearly 6,000 kg of banned plastic in a year's time. As per the directives of PMC, manufacturing, importing, stocking, distribution, and sale of single-use plastic has been banned. These items include plastic and polypropylene bags. PMC has given directives based on the lines of the central govt's order in 2022. The ban has been introduced on wrapping or packaging films around sweet boxes, plastic cutlery, straws, and plastic sticks for balloons and ear buds, invitation cards, cigarette packets, etc. According to PMC officials, the civic administration has been carrying out the drive at 15 ward offices. The squad vehicles are being used at multiple ward offices. But after the induction of 10 more vehicles, each ward office will have one dedicated vehicle. "As more vehicles are available, the civic staff will be able to carry out more actions with the added vehicles. Awareness about public sanitation is being done," said Sandip Kadam, head of PMC's solid waste department. According to citizens, new-age technologies should be used to prevent nuisances such as spitting in public places. "Littering may lead to health hazards. Spitting can lead to spread of airborne diseases. Burning of garbage can also be hazardous to health and environment," said Ketaki Paranjape, a resident of Sinhagad Road. Chinmay Joshi of Katraj said that more manpower should be deployed at locations like markets, traffic signals, and bus stops. "Many private and public establishments have CCTVs near such crowded places. These are being used to catch traffic violators and solve criminal cases. The administration should also keep a watch on people defacing or littering civic areas using these cameras," he said. "After any celebration in the city, the streets lie in squalor. It takes a few days, and sometimes constant follow ups with the ward offices for the litter to be cleared. I have noticed lack of garbage bins along Wanowrie, NIBM Road and Camp, which may be the reason why there is so much litter around," said Shruti Desai, a resident of Wanowrie. As per civic officials, the action is being taken under special solid waste management guidelines approved by PMC in 2016. These guidelines have described a number of offences. These include garbage burning, open defecation, non-segregation of wet and dry garbage, throwing trash in public places, not handing over garbage to ragpickers. Along with the regular action, drives to catch the offenders are also carried out during festive periods. The fine ranges between Rs 200 and Rs 1,000 for each offence. Pune: The civic body plans to step up action against littering in public places by doubling the number of flying squad vehicles. Ten new vehicles will be added to the flying squads, which will catch offenders found violating solid waste management guidelines for public sanitation. Earlier, PMC had only 8 vehicles. Fines will be levied for offences like spitting in public places, using banned plastic, garbage burning, and throwing trash in public areas. Pune Municipal Corporation (PMC) has filed over 72,000 cases and collected fines of Rs 4 crore from violators since Oct 2023. PMC has confiscated nearly 6,000 kg of banned plastic in a year's time. As per the directives of PMC, manufacturing, importing, stocking, distribution, and sale of single-use plastic has been banned. These items include plastic and polypropylene bags. PMC has given directives based on the lines of the central govt's order in 2022. The ban has been introduced on wrapping or packaging films around sweet boxes, plastic cutlery, straws, and plastic sticks for balloons and ear buds, invitation cards, cigarette packets, etc. According to PMC officials, the civic administration has been carrying out the drive at 15 ward offices. The squad vehicles are being used at multiple ward offices. But after the induction of 10 more vehicles, each ward office will have one dedicated vehicle. "As more vehicles are available, the civic staff will be able to carry out more actions with the added vehicles. Awareness about public sanitation is being done," said Sandip Kadam, head of PMC's solid waste department. According to citizens, new-age technologies should be used to prevent nuisances such as spitting in public places. "Littering may lead to health hazards. Spitting can lead to spread of airborne diseases. Burning of garbage can also be hazardous to health and environment," said Ketaki Paranjape, a resident of Sinhagad Road. Chinmay Joshi of Katraj said that more manpower should be deployed at locations like markets, traffic signals, and bus stops. "Many private and public establishments have CCTVs near such crowded places. These are being used to catch traffic violators and solve criminal cases. The administration should also keep a watch on people defacing or littering civic areas using these cameras," he said. "After any celebration in the city, the streets lie in squalor. It takes a few days, and sometimes constant follow ups with the ward offices for the litter to be cleared. I have noticed lack of garbage bins along Wanowrie, NIBM Road and Camp, which may be the reason why there is so much litter around," said Shruti Desai, a resident of Wanowrie. As per civic officials, the action is being taken under special solid waste management guidelines approved by PMC in 2016. These guidelines have described a number of offences. These include garbage burning, open defecation, non-segregation of wet and dry garbage, throwing trash in public places, not handing over garbage to ragpickers. Along with the regular action, drives to catch the offenders are also carried out during festive periods. The fine ranges between Rs 200 and Rs 1,000 for each offence. Stay updated with the latest news on Times of India . Don't miss daily games like Crossword , Sudoku , Location Guesser and Mini Crossword .Seattle Seahawks at Arizona Cardinals odds, picks and predictions

Trump is filling his administration with former rivals. Here’s why that could matter

Photo: Shedeur Sanders Reveals Custom Giants Cleats for Colorado's Bowl Game vs. BYUOverhauls of 'heritage brands' raise the question: How important are our products to our identities?

Column: Democrats take aim at Virginia’s marriage amendmentThe Eras Tour May Be Over — But You Can Still Grab These Taylor Swift Sweatshirts at Walmart